Lumanity

Associated interview study? Standalone study? Or in-trial interviews? Alternatives are often pursued with the intent of limiting burden on sites and participants. But in-trial interviews can be designed to maximize participation while aiming for seamless implementation, and offer several practical advantages: ✅ Fewer IRB/ethics hurdles ✅ Less paperwork for participants, with no separate consent ✅ Better recruitment coordination and success ✅ Lower fees and budget impact Conducted with the actual trial population, in-trial interviews also ensure that the findings relate directly to your endpoints. #LumanityPerspectives #PCO #PatientVoice #HTA

In-trial interviews can reveal treatment benefits beyond those measured by clinical outcome assessments (COAs). Open-ended questions let patients describe their experience in their own words. These findings provide context and meaning behind COAs and endpoints and may even reveal benefits not previously anticipated. Together, these insights can make a value story more credible and complete. This is just one of the benefits explored in our whitepaper, where our experts draw on experience from more than 50 in-trial interview studies across 20+ countries and multiple indications. #LumanityPerspectives #PCO #PatientVoice #HTA

The question is no longer whether to include in-trial interviews in a clinical program, but how to implement them. Lumanity's patient-centered outcomes team has conducted over 50 in-trial interview studies across more than 20 countries. Read our whitepaper, where our experts share their experience and explain why regulators and HTA bodies increasingly value patient experience data to complement quantitative evidence and strengthen value narratives. #LumanityPerspectives #PCO #PatientVoice #HTA

Qualitative patient experience data are increasingly valued by regulators, and HTA bodies yet remain underused in submissions. This gap is an opportunity. Sponsors who build in-trial interviews into their programs early are better positioned to tell a clearer, more credible story to strengthen their value narratives. In our whitepaper Laura Tesler Waldman and Elizabeth Hribal dive deeper into the benefits of in-trial interviews and the advantages they offer for generating meaningful findings across drug development phases. #LumanityPerspectives #PCO #PatientVoice #HTA

In multiple myeloma, treatment sequencing, longer post-progression survival, and competing mortality from comorbidities can make it difficult to attribute an overall survival effect to the treatment under study. In our recent webinar "Endpoints That Matter: A Framework for Identifying and Integrating Patient-Relevant Outcomes Across Evidence Development and Assessment", a panel of clinical, patient advocacy, pharmaceutical industry, and health economic experts unpacked a practical 4-stage framework for identifying, measuring, and communicating patient-relevant endpoints to health technology assessment bodies. Check out the on-demand recording.

ICYMI: In partnership with ISPOR, our Chief Scientific Officer (HEOR), Dan Gladwell, joined a cross-functional panel for the webinar "Endpoints That Matter: A Framework for Identifying and Integrating Patient-Relevant Outcomes Across Evidence Development and Assessment." He was joined by Åse Bratland, Antonella Cardone, and Jose Diaz, who together bring clinical, patient advocacy, pharmaceutical industry, and health economic perspectives to one of oncology's toughest evidence generation questions: “What if the endpoint driving your evidence strategy isn't the one that matters most to patients?” Watch the on-demand recording to see how this framework can strengthen your evidence strategy.